| Gene symbol | CLU | Synonyms | AAG4, APO-J, APOJ, CLI, CLU1, CLU2, KUB1, NA1/NA2, SGP-2, SGP2, SP-40, TRPM-2, TRPM2 | Type of gene | protein-coding |
| Chromosome | 8 | Map location | 8p21.1 | dbXrefs | |
| Description | clusterin | ||||
| GTO ID | GTC0572 |
| Trial ID | 2010-021011-16 |
| Disease | Prostate Cancer |
| Altered gene | CLU |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | OGX-011|custirsen sodium|TV-1011 |
| Phase | Phase3 |
| Recruitment status | Completed |
| Title | A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination with Custirsen (OGX-011) in Men with Metastatic Castrate Resistant Prostate Cancer |
| Year | 2010 |
| Country | Belgium|Canada|France|Germany|Hungary|Israel|Italy|Korea,Republic of|Netherlands|Spain|United Kingdom|United States |
| Company sponsor | Teva Pharmaceutical Industries, Ltd |
| Other ID(s) | NCT01188187 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||||||
|
|||||||||||||